Safa Can Efil

You are already at the latest version Background: Reliable biomarkers to predict response to immune checkpoint inhibitors (ICIs) in non–small cell lung cancer (NSCLC) remains limited.ABO blood group antigens may influence tumor immunity and response to immunotherapy. Methods: We retrospectively analyzed patients with advanced NSCLC treated with ICIs between 2019 and 2024. Patients were classified according to ABO blood group.

CONFLICT OF INTEREST STATEMENT The authors have no conflict of interest to declare. Supporting Information Filename Description ijc70169-sup-0001-supinfo.pdfPDF document, 396.7 KB Supplementary Figure 1: Forest plots presenting subgroup analyses evaluating the association between concomitant renin–angiotensin–aldosterone system inhibitors (RAASi) use and survival outcomes across predefined clinical variables. (A) Overall survival. (B) Progression-free survival.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.